ClinicalTrials.gg
CompletedNCT04036227Updated Oct 11, 2023Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

A Phase 1 interventional study of GS-248 and Placebo in Healthy, sponsored by Gesynta Pharma AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Gesynta Pharma AB · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy subjects.

Read the detailed description

Part I (SAD); In the SAD part of the study, single oral doses of GS-248 will be administered in 6 sequential cohorts, each consisting of 8 subjects randomised to receive either GS 248 or placebo in a 3:1 ratio. The first 2 subjects in each cohort will be dosed in a sentinel fashion; 1 subject will receive GS-248 and the other will receive placebo as randomised. The subjects will be carefully monitored by clinical staff during and after dosing. Vital signs, safety laboratory and ECG will be checked at regular intervals.

Part II (MAD); The MAD part of the study will explore multiple ascending dosing of GS-248 administered for 10 days. The proposed starting dose is 25 mg/day. However, the starting dose as well as subsequent dose levels may be adjusted based on safety and PK evaluation in previous cohorts. GS-248 will be administered in 4 sequential cohorts, each of 8 subjects randomised to receive either GS 248 or placebo in a 3:1 ratio. The subjects will be carefully monitored by clinical staff during and after dosing. Vital signs, safety laboratory and ECG will be checked at regular intervals.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written for participation in the study.
  2. Male and female healthy subjects aged 18-70 years inclusive (Part I [SAD]) and 40-75 years inclusive (Part II [MAD])
  3. Women of child bearing potential must practice abstinence or must agree to use a highly effective method of with a failure rate of \< 1% to prevent pregnancy from at least 4 weeks prior to dose to 4 weeks after last dose. Their male partner must agree to use a condom during the same time frame. Women of non- are defined as pre-menopausal females who are sterilised or defined as 12 months of amenorrhea.

    Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above).

  4. (BMI) ≥ 19 and ≤ 30 kg/m2.
  5. Subjects must be in good health as determined by medical history, physical examination, vital signs, 12-lead and clinical laboratory assessments at the time of screening, as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to any components of the GS-248 formulation.
  2. Females who are breast feeding or plan to be pregnant.
  3. Positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and within 24 h prior to the first administration of Medicinal Product (IMP).
  4. Use of (inhaled and systemic), NSAIDs (including e.g. coxibs and aspirin), antacids, Proton pump inhibitors (PPIs) or any medication that changes gastric pH within 2 weeks prior to the (first) administration of IMP.
  5. Regular use of any prescribed or non-prescribed medication including analgesics, herbal remedies, vitamins and minerals within 2 weeks prior to the (first) administration of IMP, except hormonal and occasional intake of paracetamol (maximum 2000 mg/day; and not exceeding 3000 mg/week) and nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.
  6. Inherited or acquired disorders of function, bleeding or coagulation.
  7. Presence of any acute or chronic disease that could interfere with the subject's safety during the clinical study or expose the subject to undue risk.
  8. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:

    • Systolic blood pressure \<90 or >140 mmHg, or
    • Diastolic blood pressure \<50 or >90 mmHg, or
    • Pulse \<40 or >90 bpm
  9. Any positive result on screening for serum surface antigen (HBsAg), virus antibodies (HCVAb) or (HIV) 1 and/or 2 antibodies at screening.
  10. Presence or history of drug and/or alcohol abuse and/or excessive intake of alcohol and/or history, or current use, of anabolic steroids, as judged by the Investigator.
  11. Any positive result for drug abuse and/or alcohol at screening or on admission to the unit prior to administration of the IMP.
  12. Participation in another clinical study with an experimental drug within 3 months before the administration of IMP.
  13. Consumption of grapefruit or grapefruit juice within 14 days of study drug administration.
  14. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  15. within the past 5 years with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.
  16. Any planned major surgery within the duration of the study.
  17. Prolonged (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting at the time of screening, as judged by the Investigator.
  18. Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, chewing tobacco) less than 3 times per week is allowed before screening visit.
  19. Regular excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages.
  20. Intake of xanthine and/or taurine containing energy drinks within 2 days prior to screening.
  21. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
  22. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    GS-248

    Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses) Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I.

    Drug: GS-248

  • Placebo comparator
    Placebo

    Matching placebo oral solution

    Drug: Placebo

Interventions

  • DrugGS-248

    GS-248 oral solution

  • DrugPlacebo

    Placebo oral solution with the same composition to match active drug

06

What researchers measure

Primary outcomes

  1. Number of Treatment Related Adverse Events

    AEs were assessed as 'unlikely', 'possibly' or 'probably' related to the IMP. 'Possibly' and 'probably' were categorized as treatment related.

    Time frame: AEs were collected from the start of IMP administration until the end-of-study visit of each part, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).

  2. Clinically Significant Changes in ECG

    Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. Heart rate and PQ/PR, QRS, QT and QTcF intervals were recorded. Ambulatory ECG telemetry was used for cardiac surveillance up to 24 h after IMP administration in the SAD part of the study.

    Time frame: 12-lead ECG was measured at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).

  3. Clinically Significant Changes in Vital Signs

    Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Body temperature was measured orally using a digital thermometer.

    Time frame: Vital signs was checked at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).

  4. Clinically Significant Changes in Safety Laboratory Parameters

    Blood samples for analysis of clinical chemistry, haematology and coagulation parameters.

    Time frame: Blood samples were collected at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).

  5. Clinically Significant Changes in Physical Examination

    A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.

    Time frame: Physical examination was performed at pre-defined timepoints from the screening visit until the end-of- study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).

Secondary outcomes

  1. Cmax:

    Maximum plasma concentration.

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD Day 1-3 (first dose) and Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  2. Tmax:

    Time to Cmax.

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD: Day 1-3 (first dose) Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  3. T½:

    Terminal elimination half-life

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  4. AUC0-t:

    Area under the concentration time curve from the time of dosing to the time of the last observation.

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  5. AUC 0-inf

    Area under the curve from time 0 to infinity.

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose

  6. AUCss

    Area under the plasma concentration curve during a dosing interval at steady state.

    Time frame: MAD: Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  7. Clearance (CL)/F:

    Apparent total body clearance following extravascular administration.

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  8. Vz/F:

    Apparent volume of distribution following extravascular administration

    Time frame: SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

  9. Accumulation Ratio AUC 0-ss

    Time frame: MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.

Other outcomes

  1. mPGES-1 Activity

    Ex vivo determination of mPGES-1 activity in a Whole Blood Assay (WBA) measured as percent change from baseline of Prostaglandin E2 (PGE2) levels after lipopolysaccharide (LPS) stimulation.

    Time frame: At 24h after first dose Day 1 and at 24 hours after last dose Day 10.

07

Results

Posted Sep 8, 2023
Limitations and caveats
Part I=SAD was completed in full. Part II=MAD was completed after three of four cohorts. Reason: Systemic exposure of GS-248 was considered sufficiently high after 3 MAD cohorts. Part III= Systemic sclerosis patients was cancelled. Reason: Decision by Sponsor that performing this part would not add scientific value to the development programme for GS-248. Part IV=Celecoxib was completed in full. Only celecoxib given in this exploratory comparison and thus results excluded in result section.

Participant flow

Subjects were recruited from CTC's database of healthy volunteers and from advertising in media (including social media). Screening visits were performed at CTC research clinic. Part I (SAD): Recruitment period started 19JUN2019 and lasted until 15OCT2019. Part II (MAD): Recruitment period started in August 2019 (when first SAD cohorts had been completed) and lasted until 25NOV2019.

Part I (SAD): 1 mg
Participant flow — Part I (SAD): 1 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started60000000000
Completed60000000000
Not completed00000000000
Part I (SAD): 5 mg
Participant flow — Part I (SAD): 5 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started06000000000
Completed06000000000
Not completed00000000000
Part I (SAD): 8 mg
Participant flow — Part I (SAD): 8 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00600000000
Completed00600000000
Not completed00000000000
Part I (SAD): 40 mg
Participant flow — Part I (SAD): 40 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00060000000
Completed00060000000
Not completed00000000000
Part I (SAD): 100 mg
Participant flow — Part I (SAD): 100 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00006000000
Completed00006000000
Not completed00000000000
Part I (SAD): 300 mg
Participant flow — Part I (SAD): 300 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00000600000
Completed00000600000
Not completed00000000000
Part I (SAD): Placebo
Participant flow — Part I (SAD): Placebo
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started000000120000
Completed000000120000
Not completed00000000000
Part II (MAD): 20 mg
Participant flow — Part II (MAD): 20 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00000006000
Completed00000006000
Not completed00000000000
Part II (MAD): 60 mg
Participant flow — Part II (MAD): 60 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00000000600
Completed00000000600
Not completed00000000000
Part II (MAD): 180 mg
Participant flow — Part II (MAD): 180 mg
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00000000060
Completed00000000050
Not completed00000000010
Part II (MAD): Placebo
Participant flow — Part II (MAD): Placebo
MilestonePart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
Started00000000006
Completed00000000006
Not completed00000000000

Outcome measures

PrimaryNumber of Treatment Related Adverse Events

AEs were assessed as 'unlikely', 'possibly' or 'probably' related to the IMP. 'Possibly' and 'probably' were categorized as treatment related.

Time frame:
AEs were collected from the start of IMP administration until the end-of-study visit of each part, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).
Reported as:
Number · Number of events
Number of Treatment Related Adverse Events
Number of eventsGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)Placebo (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)Placebo (MAD)
Number of Treatment Related Adverse Events340321411290
PrimaryClinically Significant Changes in ECG

Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. Heart rate and PQ/PR, QRS, QT and QTcF intervals were recorded. Ambulatory ECG telemetry was used for cardiac surveillance up to 24 h after IMP administration in the SAD part of the study.

Time frame:
12-lead ECG was measured at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Reported as:
Number · Number of abnormal CS events
Clinically Significant Changes in ECG
Number of abnormal CS eventsGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)Placebo (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)Placebo (MAD)
Clinically Significant Changes in ECG00000001000
PrimaryClinically Significant Changes in Vital Signs

Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Body temperature was measured orally using a digital thermometer.

Time frame:
Vital signs was checked at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part 1 (SAD) and 20 days in Part 2 (MAD).
Reported as:
Number · Number of abnormal CS events
Clinically Significant Changes in Vital Signs
Number of abnormal CS eventsGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)Placebo (SAD)Total (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)Placebo (MAD)Total (MAD)
Clinically Significant Changes in Vital Signs0000000000000
PrimaryClinically Significant Changes in Safety Laboratory Parameters

Blood samples for analysis of clinical chemistry, haematology and coagulation parameters.

Time frame:
Blood samples were collected at pre-defined timepoints from the screening visit until the end-of-study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Reported as:
Count of participants · Participants
Clinically Significant Changes in Safety Laboratory Parameters
ParticipantsGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)Placebo (SAD)Total (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)Placebo (MAD)Total (MAD)
Clinically Significant Changes in Safety Laboratory Parameters0000000002013
PrimaryClinically Significant Changes in Physical Examination

A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities.

Time frame:
Physical examination was performed at pre-defined timepoints from the screening visit until the end-of- study visit, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).
Reported as:
Count of participants · Participants
Clinically Significant Changes in Physical Examination
ParticipantsGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)Placebo (SAD)Total (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)Placebo (MAD)Total (MAD)
Clinically Significant Changes in Physical Examination0000000000112
SecondaryCmax:

Maximum plasma concentration.

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD Day 1-3 (first dose) and Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · nmol/L
Cmax:
nmol/LGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD First Dose)GS-248 60 mg (MAD First Dose)GS-248 180 mg MAD (First Dose)GS-248 20 mg (MAD Last Dose)GS-248 60 mg (MAD Last Dose)GS-248 180 mg MAD (Last Dose)
Cmax:1.247 ± 0.95378.975 ± 4.97111.82 ± 4.365145.3 ± 69.75263.3 ± 65.07818.3 ± 783.341.47 ± 18.45231.8 ± 187.3478.5 ± 310.043.93 ± 30.10176.5 ± 83.04903.0 ± 590.6
SecondaryTmax:

Time to Cmax.

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose; MAD: Day 1-3 (first dose) Day 10-12 (last dose): pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Median · hours
Tmax:
hoursGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD First Dose)GS-248 60 mg (MAD First Dose)GS-248 180 mg (MAD First Dose)GS-248 20 mg (MAD Last Dose)GS-248 60 mg (MAD Last Dose)GS-248 180 mg (MAD Last Dose)
Tmax:1.500 (1.00 to 1.50)2.500 (1.50 to 3.00)1.000 (1.00 to 2.00)1.000 (0.500 to 1.50)1.000 (0.500 to 1.50)1.500 (1.00 to 2.00)1.000 (0.500 to 2.00)1.000 (0.500 to 1.00)1.108 (0.517 to 2.00)2.000 (1.00 to 2.00)1.000 (0.500 to 2.02)2.000 (1.02 to 2.05)
SecondaryT½:

Terminal elimination half-life

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · hours
T½:
hoursGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD First Dose)GS-248 60 mg (MAD First Dose)GS-248 180 mg (MAD First Dose)GS-248 20 mg (MAD Last Dose)GS-248 60 mg (MAD Last Dose)GS-248 180 mg (MAD Last Dose)
T½:4.539 ± 2.4351.089 ± 0.18791.660 ± 0.36849.220 ± 6.6979.513 ± 3.68311.14 ± 1.6303.469 ± 2.0736.705 ± 3.12011.86 ± 10.766.504 ± 3.98018.00 ± 8.75015.01 ± 5.225
SecondaryAUC0-t:

Area under the concentration time curve from the time of dosing to the time of the last observation.

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · h*nmol/L
AUC0-t:
h*nmol/LGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD First Dose)GS-248 60 mg (MAD First Dose)GS-248 180 mg (MAD First Dose)GS-248 20 mg (MAD Last Dose)GS-248 60 mg (MAD Last Dose)GS-248 180 mg (MAD Last Dose)
AUC0-t:2.437 ± 1.84630.57 ± 22.8839.08 ± 13.40478.6 ± 285.3879.8 ± 380.02667 ± 2850180.1 ± 75.75655.8 ± 473.71735 ± 1164211.0 ± 115.5650.5 ± 267.24798 ± 3702
SecondaryAUC 0-inf

Area under the curve from time 0 to infinity.

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose
Reported as:
Mean · h*nmol/L
AUC 0-inf
h*nmol/LGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)
AUC 0-inf8.542 ± 0.843840.22 ± 24.6241.77 ± 13.80489.3 ± 282.3894.7 ± 380.82713 ± 2906
SecondaryAUCss

Area under the plasma concentration curve during a dosing interval at steady state.

Time frame:
MAD: Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · h*nmol/L
AUCss
h*nmol/LGS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)
AUCss205.9 ± 103.4604.6 ± 233.14046 ± 2823
SecondaryClearance (CL)/F:

Apparent total body clearance following extravascular administration.

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · L/h
Clearance (CL)/F:
L/hGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD First Dose)GS-248 60 mg (MAD First Dose)GS-248 180 mg (MAD First Dose)GS-248 20 mg (MAD Last Dose)GS-248 60 mg (MAD Last Dose)GS-248 180 mg (MAD Last Dose)
Clearance (CL)/F:173.7 ± 17.51228.2 ± 102.7304.8 ± 83.80161.4 ± 92.39184.8 ± 58.74318.2 ± 223.4187.0 ± 79.05190.2 ± 109.1181.2 ± 101.4175.4 ± 81.81166.2 ± 63.6297.59 ± 74.02
SecondaryVz/F:

Apparent volume of distribution following extravascular administration

Time frame:
SAD: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose); MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · L
Vz/F:
LGS-248 1 mg (SAD)GS-248 5 mg (SAD)GS-248 8 mg (SAD)GS-248 40 mg (SAD)GS-248 100 mg (SAD)GS-248 300 mg (SAD)GS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)
Vz/F:1097 ± 516.4341.9 ± 120.5719.7 ± 192.12117 ± 24452378 ± 918.84856 ± 33941354 ± 392.33945 ± 16852157 ± 2139
SecondaryAccumulation Ratio AUC 0-ss
Time frame:
MAD: Day 1-3 and Day 10-12: pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose.
Reported as:
Mean · ratio
Accumulation Ratio AUC 0-ss
ratioGS-248 20 mg (MAD)GS-248 60 mg (MAD)GS-248 180 mg (MAD)
Accumulation Ratio AUC 0-ss1.148 ± 0.31481.171 ± 0.55412.390 ± 1.135
Other pre-specifiedmPGES-1 Activity

Ex vivo determination of mPGES-1 activity in a Whole Blood Assay (WBA) measured as percent change from baseline of Prostaglandin E2 (PGE2) levels after lipopolysaccharide (LPS) stimulation.

Time frame:
At 24h after first dose Day 1 and at 24 hours after last dose Day 10.
Reported as:
Mean · Relative change from baseline (%)
mPGES-1 Activity
Relative change from baseline (%)Day 1 (SAD): 5 mgDay 1 (SAD): 40 mgDay 1 (SAD): 100 mgDay 1 (SAD): 300 mgDay 1 (MAD): 20 mgDay 1 (MAD): 60 mgDay 1 (MAD): 180 mgDay 1 (SAD and MAD): PlaceboDay 10 (MAD): 20 mgDay 10 (MAD): 60 mgDay 10 (MAD): 180 mgDay 10 (MAD): Placebo
mPGES-1 Activity7.2 ± 98.8-97.1 ± 12.1-108.3 ± 11.5-105.2 ± 11.6-65.9 ± 20.2-94.9 ± 9.3-104.3 ± 6.89.8 ± 59.6-86.9 ± 26.8-104.3 ± 13.9-109.8 ± 7.818.6 ± 57.7

Adverse events

Collected over AEs (including serious AEs [SAEs]) were collected from the start of IMP application until the end-of- study visit of each part, an average of 10 days in Part I (SAD) and 20 days in Part II (MAD).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I (SAD): 1 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part I (SAD): 5 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Part I (SAD): 8 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part I (SAD): 40 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part I (SAD): 100 mg0/6 (0%)0/6 (0%)3/6 (50%)
Part I (SAD): 300 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Part I (SAD): Placebo0/12 (0%)0/12 (0%)5/12 (41.7%)
Part II (MAD): 20 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part II (MAD): 60 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part II (MAD): 180 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part II (MAD): Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPart I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): Placebo
HeadacheNervous system disorders2/63/60/60/61/62/62/121/62/61/61/6
Abdominal painGastrointestinal disorders0/60/60/60/60/60/60/120/60/62/62/6
DiarrhoeaGastrointestinal disorders0/60/60/60/60/60/60/120/62/61/60/6
FlatulenceGastrointestinal disorders0/60/60/60/60/60/60/121/62/61/60/6
RashSkin and subcutaneous tissue disorders0/60/60/60/60/60/60/120/60/62/61/6
ConstipationGastrointestinal disorders0/60/60/60/60/61/60/120/60/60/60/6
Lip dryGastrointestinal disorders0/61/60/60/60/60/60/120/60/60/60/6
NauseaGastrointestinal disorders0/61/60/61/60/60/60/120/61/60/60/6
VomitingGastrointestinal disorders1/60/60/60/60/60/60/120/60/60/60/6
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/60/60/60/60/60/120/60/60/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD)40.7 ± 21.533.7 ± 9.836.8 ± 21.441.8 ± 15.950.7 ± 10.833.7 ± 13.032.4 ± 14.1————37.8 ± 15.8
Part II (MAD)———————56.7 ± 12.258.2 ± 11.058.2 ± 12.259.0 ± 13.958.0 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD) — Female2313443————20
Part I (SAD) — Male4353229————28
Part II (MAD) — Female———————444315
Part II (MAD) — Male———————22239
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD) — Hispanic or Latino000100000001
Part I (SAD) — Not Hispanic or Latino66656612000047
Part I (SAD) — Unknown or Not Reported000000000000
Part II (MAD) — Hispanic or Latino———————00000
Part II (MAD) — Not Hispanic or Latino———————666624
Part II (MAD) — Unknown or Not Reported———————00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
part I (MAD) — American Indian or Alaska Native000000000000
part I (MAD) — Asian210000100004
part I (MAD) — Native Hawaiian or Other Pacific Islander000000000000
part I (MAD) — Black or African American000000000000
part I (MAD) — White45666611000044
part I (MAD) — More than one race000000000000
part I (MAD) — Unknown or Not Reported000000000000
Part II (MAD) — American Indian or Alaska Native———————00000
Part II (MAD) — Asian———————00000
Part II (MAD) — Native Hawaiian or Other Pacific Islander———————00000
Part II (MAD) — Black or African American———————00000
Part II (MAD) — White———————666624
Part II (MAD) — More than one race———————00000
Part II (MAD) — Unknown or Not Reported———————00000
Region of Enrollment
Region of Enrollment(participants)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Sweden66666612666672
BMI
BMI(kg/m^2)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD)22.3 ± 2.625.2 ± 3.925.2 ± 3.425.7 ± 3.426.0 ± 2.222.0 ± 2.024.0 ± 3.0————24.4 ± 3.2
Part II (MAD)———————26.0 ± 1.323.5 ± 2.724.3 ± 1.625.8 ± 3.524.9 ± 2.5
Height
Height(cm)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD)171.3 ± 13.6169.0 ± 11.0178.0 ± 4.4176.7 ± 13.9176.2 ± 9.6173.3 ± 10.3175.7 ± 10.4————174.1 ± 10.6
Part II (MAD)———————171.0 ± 11.9171.7 ± 8.0172.2 ± 6.8176.0 ± 12.7172.7 ± 9.7
Weight
Weight(kg)Part I (SAD): 1 mgPart I (SAD): 5 mgPart I (SAD): 8 mgPart I (SAD): 40 mgPart I (SAD): 100 mgPart I (SAD): 300 mgPart I (SAD): PlaceboPart II (MAD): 20 mgPart II (MAD): 60 mgPart II (MAD): 180 mgPart II (MAD): PlaceboTotal
Part I (SAD)65.7 ± 13.472.5 ± 16.979.8 ± 13.381.0 ± 18.081.0 ± 11.066.3 ± 8.274.7 ± 13.8————74.4 ± 14.5
Part II (MAD)———————76.2 ± 9.069.8 ± 11.972.3 ± 5.581.0 ± 17.274.8 ± 11.7
08

Study locations

1 site
  • CTC Clinical Trial Consultants AB
    Uppsala, SE-75237, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Dec 2019, 5 months.

Results were first posted in Sep 2023, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Jul 29, 2019
StartActual
Jul 3, 2019
Primary completionActual
Dec 20, 2019
CompletionActual
Dec 20, 2019
Results first posted
Sep 8, 2023
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04036227
Lead sponsor
Gesynta Pharma AB
Collaborators
CTC Clinical Trial Consultants AB
Responsible party
Sponsor
First posted
Jul 29, 2019
Start date
Jul 3, 2019
Primary completion
Dec 20, 2019
Completion
Dec 20, 2019
Results posted
Sep 8, 2023
Last update
Oct 11, 2023

Study contacts

Folke Sjöberg, MD
principal investigator · CTC Clinical Trial Consultants AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vipoglanstat

Start the discussion